Anzeige
Mehr »
Login
Mittwoch, 04.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Analysten eilen, um Kursziele zu verdreifachen nach ATHAs neuester Entdeckung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

GlobeNewswire (Europe)-Archiv vom 25.05.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
25.05.Samhällsbyggnadsbolaget i Norden AB: SBB establishes a new joint venture with Castlelake which signs a loan agreement of approximately SEK 5.7 billion313Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") has agreed to enter into a joint venture, SBB Social Facilities AB ("SBB Social Facilities"), together with funds managed by global alternative investment...
► Artikel lesen
25.05.Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress20772-week data consistent with disease modification in IgAN, selected as a best-ranked abstract;Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater...
► Artikel lesen
25.05.Novartis Pharma AG: Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio959In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction...
► Artikel lesen
25.05.Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo925Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical...
► Artikel lesen
25.05.MacDonald Mines Exploration Ltd.: MacDonald Mines Withdraws Previously Announced Scadding Gold Project Assays Pending Further Review1.381TORONTO, May 24, 2024 (GLOBE NEWSWIRE) -- MacDonald Mines Exploration Ltd. (TSX-V: BMK, OTC: MCDMF) ("MacDonald Mines" or the "Company") has discovered inconsistencies in certain assay results from...
► Artikel lesen
25.05.BioRestorative Therapies, Inc: BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice775MELVILLE, N.Y., May 24, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies...
► Artikel lesen